Three-Drug attack on tough breast cancer
NCT ID NCT07161791
Summary
This study is testing a new combination of three drugs for advanced triple-negative breast cancer that has progressed after initial treatment. It will enroll 12 patients to see if adding an anti-fibrosis drug (pirfenidone) to an immunotherapy (camrelizumab) and chemotherapy can help control the cancer. The main goal is to measure how many patients' tumors shrink or stop growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.